{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:21:24Z","timestamp":1762431684318,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.transci.2019.08.019","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T11:18:50Z","timestamp":1568632730000},"page":"669-673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["HLA-DRB1*01:01, but not HLA-DRB1:1503 or HLA-DRB1*11, is associated with decreased inhibitor risk in Iranian hemophilia A patients"],"prefix":"10.1016","volume":"58","author":[{"given":"S.","family":"Hosseini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-9788","authenticated-orcid":false,"given":"S.","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Yari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pourfatollah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Rezaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Moazezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-2928","authenticated-orcid":false,"given":"A.","family":"Aghaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.transci.2019.08.019_bib0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/hae.12105","article-title":"Factor VIII genotype characterization of haemophilia A affected patients with transient and permanent inhibitors: a comprehensive Argentine study of inhibitor risks","volume":"19","author":"Rossetti","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.transci.2019.08.019_bib0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"10.1016\/j.transci.2019.08.019_bib0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2516.2004.01011.x","article-title":"HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation","volume":"10","author":"Bril","year":"2004","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.transci.2019.08.019_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003066","article-title":"Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment","volume":"9","author":"Pandey","year":"2013","journal-title":"PLoS Comput Biol"},{"issue":"7","key":"10.1016\/j.transci.2019.08.019_bib0025","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2014-09-599365","article-title":"Factor VIII gene variants and inhibitor risk in African American hemophilia A patients","volume":"126","author":"Gunasekera","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2019.08.019_bib0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2516.2008.01874.x","article-title":"Occurrence of haemophilia in Iran","volume":"15","author":"Mehdizadeh","year":"2009","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.transci.2019.08.019_bib0035","first-page":"66","article-title":"Prevalence of inhibitors in a population of 1280 Hemophilia A patients in Iran","volume":"41","author":"Sharifian","year":"2003","journal-title":"Acta Med Iran"},{"issue":"3","key":"10.1016\/j.transci.2019.08.019_bib0040","first-page":"131","article-title":"Frequency of Hepatitis B and C infection among Hemophiliac patients in Kerman","volume":"11","author":"Zahedi","year":"2004","journal-title":"J Kerman Univ Med Sci"},{"issue":"Suppl. 77","key":"10.1016\/j.transci.2019.08.019_bib0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ejh.12495","article-title":"Genetic risk factors for inhibitors in haemophilia A","volume":"94","author":"Bardi","year":"2015","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.transci.2019.08.019_bib0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hae.12004","article-title":"F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort","volume":"19","author":"Schwarz","year":"2013","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.transci.2019.08.019_bib0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2516.2011.02700.x","article-title":"F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race\/ethnicity","volume":"18","author":"Miller","year":"2012","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.transci.2019.08.019_bib0060","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1111\/j.1365-2516.2011.02604.x","article-title":"Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the south of Brazil","volume":"18","author":"De Barros","year":"2012","journal-title":"Haemophilia"},{"issue":"102","key":"10.1016\/j.transci.2019.08.019_bib0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2516.2008.01976.x","article-title":"HLA genotype in patients with acquired haemophilia A","volume":"16","author":"Pavlova","year":"2010","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.transci.2019.08.019_bib0070","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1655945","article-title":"HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII","volume":"77","author":"Oldenburg","year":"1997","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.transci.2019.08.019_bib0075","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1655944","article-title":"HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party","volume":"77","author":"Hay","year":"1997","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.transci.2019.08.019_bib0080","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"9371","key":"10.1016\/j.transci.2019.08.019_bib0085","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.transci.2019.08.019_bib0090","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2516.2007.01522.x","article-title":"A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil","volume":"13","author":"Ozelo","year":"2007","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.transci.2019.08.019_bib0095","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0198-8859(01)00320-2","article-title":"Human leukocyte antigen class II allele frequencies and haplotype association in Iranian normal population","volume":"62","author":"Amirzargar","year":"2001","journal-title":"Hum Immunol"},{"issue":"2","key":"10.1016\/j.transci.2019.08.019_bib0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.arcmed.2007.09.009","article-title":"Frequencies of HLA-DRB1 in Iranian normal population and in patients with acute lymphoblastic leukemia","volume":"39","author":"Yari","year":"2008","journal-title":"Arch Med Res"},{"issue":"1","key":"10.1016\/j.transci.2019.08.019_bib0105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bjid.2013.04.007","article-title":"The association of HLA-DRB1 alleles and drug use with HIV infection in a Chinese Han Cohort","volume":"18","author":"Diao","year":"2014","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"10.1016\/j.transci.2019.08.019_bib0110","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/jth.13961","article-title":"Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement","volume":"16","author":"Spena","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.transci.2019.08.019_bib0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jth.12768","article-title":"Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay","volume":"13","author":"Boylan","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1016\/j.transci.2019.08.019_bib0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1538-7836.2009.03437.x","article-title":"Clinical prediction models for inhibitor development in severe hemophilia A","volume":"7","author":"van den Berg","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.transci.2019.08.019_bib0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/tan.12364","article-title":"The association of HLA-DRB1 and HLA-DQB1 alleles with the development of factor VIII inhibitors in severe haemophilia A patients in India","volume":"84","author":"Pinto","year":"2014","journal-title":"Tissue Antigens"},{"issue":"12","key":"10.1016\/j.transci.2019.08.019_bib0130","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2006-05-024711","article-title":"Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A","volume":"108","author":"Astermark","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2019.08.019_bib0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5505\/tjh.2012.29795","article-title":"The Association Between HLA Class II Alleles and the Occurrence of Factor VIII Inhibitor in Thai Patients with Hemophilia A","volume":"29","author":"Nathalang","year":"2012","journal-title":"Turk J Haematol"},{"issue":"5","key":"10.1016\/j.transci.2019.08.019_bib0140","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/hae.12168","article-title":"Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A","volume":"19","author":"Pergantou","year":"2013","journal-title":"Haemophilia"},{"issue":"102","key":"10.1016\/j.transci.2019.08.019_bib0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2516.2008.01905.x","article-title":"HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P","volume":"16","author":"Ettinger","year":"2010","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.transci.2019.08.019_bib0150","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"Eckhardt","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.transci.2019.08.019_bib0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2516.1999.00300.x","article-title":"Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates","volume":"5","author":"Scharrer","year":"1999","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.transci.2019.08.019_bib0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.2830420408","article-title":"Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study","volume":"42","author":"Bray","year":"1993","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.transci.2019.08.019_bib0165","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305021930182X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305021930182X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:49:16Z","timestamp":1761468556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147305021930182X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S147305021930182X"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2019.08.019","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HLA-DRB1*01:01, but not HLA-DRB1:1503 or HLA-DRB1*11, is associated with decreased inhibitor risk in Iranian hemophilia A patients","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2019.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}